(Q37644362)

21 August 2017

1 reference

title

Current perspectives of the roles of the central norepinephrine system in anxiety and depression (English)

1 reference

21 August 2017

0 references

0 references

Andrew W Goddard

1

1 reference

21 August 2017

Susan G Ball

2

1 reference

21 August 2017

James Martinez

3

1 reference

21 August 2017

Michael J Robinson

4

1 reference

21 August 2017

Charles R Yang

5

1 reference

21 August 2017

James M Russell

6

1 reference

21 August 2017

Anantha Shekhar

7

1 reference

21 August 2017

1 April 2010

1 reference

21 August 2017

Depression and Anxiety

1 reference

21 August 2017

27

1 reference

21 August 2017

339-350

1 reference

21 August 2017

4

1 reference

What is the genetic relationship between anxiety and depression?

21 August 2017

1 reference

Allostatic load in women with and without PTSD symptoms

21 January 2018

1 reference

Plasma catecholamine and lymphocyte beta 2-adrenergic receptor alterations in elderly Alzheimer caregivers under stress

21 January 2018

1 reference

Serotonin and the neurobiology of depression. Effects of tryptophan depletion in drug-free depressed patients.

21 January 2018

1 reference

Novel drugs and therapeutic targets for severe mood disorders

21 January 2018

1 reference

7 January 2021

Perturbations in brain monoamine systems during stress

1 reference

7 January 2021

Multiple feedback mechanisms activating corticotropin-releasing hormone system in the brain during stress

1 reference

7 January 2021

The organization of noradrenergic pathways from the brainstem to the paraventricular and supraoptic nuclei in the rat.

1 reference

7 January 2021

Adrenergic innervation of corticotropin releasing factor (CRF)-synthesizing neurons in the hypothalamic paraventricular nucleus of the rat. A combined light and electron microscopic immunocytochemical study.

1 reference

7 January 2021

A combined light and electron microscopic immunocytochemical method for the simultaneous localization of multiple tissue antigens. Tyrosine hydroxylase immunoreactive innervation of corticotropin releasing factor synthesizing neurons in the paravent

1 reference

7 January 2021

Evidence for local corticotropin releasing factor (CRF)-immunoreactive neuronal circuits in the paraventricular nucleus of the rat hypothalamus. An electron microscopic immunohistochemical analysis

1 reference

7 January 2021

The stress system in depression and neurodegeneration: focus on the human hypothalamus.

1 reference

7 January 2021

Targeting abnormal neural circuits in mood and anxiety disorders: from the laboratory to the clinic

1 reference

7 January 2021

An integrative theory of locus coeruleus-norepinephrine function: adaptive gain and optimal performance

1 reference

7 January 2021

Noradrenergic modulation of arousal

1 reference

7 January 2021

Network reset: a simplified overarching theory of locus coeruleus noradrenaline function

1 reference

7 January 2021

Adaptive gain and the role of the locus coeruleus-norepinephrine system in optimal performance

1 reference

7 January 2021

Physiology and neurobiology of stress and adaptation: central role of the brain

1 reference

7 January 2021

Facilitation of noradrenaline release from rat brain slices by beta-adrenoceptors

1 reference

7 January 2021

Postsynaptic alpha-2 adrenergic receptors are critical for the antidepressant-like effects of desipramine on behavior

1 reference

7 January 2021

Developmental determinants of sensitivity and resistance to stress

1 reference

7 January 2021

Single-unit response of noradrenergic neurons in the locus coeruleus of freely moving cats. II. Adaptation to chronically presented stressful stimuli.

1 reference

7 January 2021

Single-unit response of noradrenergic neurons in the locus coeruleus of freely moving cats. I. Acutely presented stressful and nonstressful stimuli

1 reference

7 January 2021

Regulation and dysregulation of the hypothalamic-pituitary-adrenal axis. The corticotropin-releasing hormone perspective

1 reference

7 January 2021

Stressors, stress, and neuroendocrine integration of the adaptive response. The 1997 Hans Selye Memorial Lecture.

1 reference

7 January 2021

Corticotropin-releasing factor neurotransmission in locus coeruleus: a possible site of antidepressant action.

1 reference

7 January 2021

Corticotropin-releasing factor, norepinephrine, and stress

1 reference

7 January 2021

The noradrenergic system in pathological anxiety: a focus on panic with relevance to generalized anxiety and phobias

1 reference

7 January 2021

Role of brain norepinephrine in the behavioral response to stress

1 reference

7 January 2021

Chronic stress: implications for neuronal morphology, function and neurogenesis.

1 reference

7 January 2021

Prefrontal cortical function and anxiety: controlling attention to threat-related stimuli.

1 reference

7 January 2021

Neurocognitive mechanisms of anxiety: an integrative account

1 reference

7 January 2021

Alpha2A and alpha2C-adrenoceptor regulation in the brain: alpha2A changes persist after chronic stress.

1 reference

7 January 2021

Adrenal insufficiency and colonic inflammation after a novel chronic psycho-social stress paradigm in mice: implications and mechanisms.

1 reference

7 January 2021

Long-term stress degenerates, but imipramine regenerates, noradrenergic axons in the rat cerebral cortex.

1 reference

7 January 2021

Effects of repeated stress on regeneration of serotonergic and noradrenergic axons in the cerebral cortex of adult rats

1 reference

7 January 2021

Stress reactivity of the brain noradrenergic system in three rat strains differing in their neuroendocrine and behavioral responses to stress: implications for susceptibility to stress-related neuropsychiatric disorders.

1 reference

7 January 2021

Role of presynaptic alpha2-adrenoceptors in antidepressant action: recent findings from microdialysis studies

1 reference

7 January 2021

Modeling a negative response bias in the human amygdala by noradrenergic-glucocorticoid interactions.

1 reference

7 January 2021

Endogenous cortisol level interacts with noradrenergic activation in the human amygdala.

1 reference

7 January 2021

Noradrenergic dysfunction and the psychopharmacology of posttraumatic stress disorder.

1 reference

7 January 2021

Immediate treatment with propranolol decreases posttraumatic stress disorder two months after trauma

1 reference

7 January 2021

The role of the noradrenergic system in emotional memory

1 reference

7 January 2021

A parallel group placebo controlled study of prazosin for trauma nightmares and sleep disturbance in combat veterans with post-traumatic stress disorder

1 reference

7 January 2021

The use of prazosin for the treatment of trauma nightmares and sleep disturbance in combat veterans with post-traumatic stress disorder

1 reference

7 January 2021

Reduction of nightmares and other PTSD symptoms in combat veterans by prazosin: a placebo-controlled study

1 reference

7 January 2021

Daytime prazosin reduces psychological distress to trauma specific cues in civilian trauma posttraumatic stress disorder.

1 reference

7 January 2021

Pharmacologic reduction of CNS noradrenergic activity in PTSD: the case for clonidine and prazosin

1 reference

7 January 2021

1 reference

7 January 2021

Generalized anxiety disorder and psychiatric comorbidities such as depression, bipolar disorder, and substance abuse.

1 reference

7 January 2021

Anxious depression and response to treatment

1 reference

7 January 2021

Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report.

1 reference

7 January 2021

Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder

1 reference

7 January 2021

Treatment outcomes for primary care patients with major depression and lifetime anxiety disorders

1 reference

7 January 2021

Effect of concurrent anxiety on response to sertraline and imipramine in patients with chronic depression

1 reference

7 January 2021

The efficacy and tolerability of duloxetine in the treatment of anxious versus non-anxious depression: a post-hoc analysis of an open-label outpatient study.

1 reference

7 January 2021

Interaction of brain noradrenergic system and the hypothalamic-pituitary-adrenal (HPA) axis in man.

1 reference

7 January 2021

The relationship between plasma MHPG and NE: employing regression models in estimating centrally derived MHPG and peripheral NE turnover rate in panic disorder.

1 reference

7 January 2021

Role of norepinephrine in the pathophysiology and treatment of mood disorders

1 reference

7 January 2021

Reduced brain norepinephrine and dopamine release in treatment-refractory depressive illness: evidence in support of the catecholamine hypothesis of mood disorders

1 reference

7 January 2021

Noradrenergic pathology in psychiatric disorders: postmortem studies

1 reference

7 January 2021

Noradrenaline in mood and anxiety disorders: basic and clinical studies.

1 reference

7 January 2021

Evidence that alpha 2-adrenergic pathways play a major role in growth hormone (GH) neuroregulation: alpha 2-adrenergic agonism counteracts the inhibitory effect of muscarinic cholinergic receptor blockade on the GH response to GH-releasing hormone,

1 reference

7 January 2021

Neuroanatomical circuits modulating fear and anxiety behaviors.

1 reference

7 January 2021

Anxious and depressive disorders and their comorbidity: effect on central nervous system noradrenergic function

1 reference

7 January 2021

TrkB regulates hippocampal neurogenesis and governs sensitivity to antidepressive treatment

1 reference

7 January 2021

Adult neurogenesis, mental health, and mental illness: hope or hype?

1 reference

7 January 2021

Neurobiology of depression: an integrated view of key findings

1 reference

7 January 2021

Adult neurogenesis is regulated by adrenal steroids in the dentate gyrus.

1 reference

7 January 2021

Adrenal steroids regulate postnatal development of the rat dentate gyrus: I. Effects of glucocorticoids on cell death.

1 reference

7 January 2021

Enhanced brain cell proliferation following early adrenalectomy in rats

1 reference

7 January 2021

Age-dependent effects of chronic stress on brain plasticity and depressive behavior

1 reference

7 January 2021

Brain-derived neurotropic factor and neurogenesis in the adult rat dentate gyrus: interactions with corticosterone

1 reference

7 January 2021

Depletion of norepinephrine decreases the proliferation, but does not influence the survival and differentiation, of granule cell progenitors in the adult rat hippocampus

1 reference

7 January 2021

Selective serotonin depletion does not regulate hippocampal neurogenesis in the adult rat brain: differential effects of p-chlorophenylalanine and 5,7-dihydroxytryptamine

1 reference

7 January 2021

The alpha2-adrenoceptor antagonist dexefaroxan enhances hippocampal neurogenesis by increasing the survival and differentiation of new granule cells

1 reference

7 January 2021

Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications

1 reference

7 January 2021

Stress, depression, and neuroplasticity: a convergence of mechanisms

1 reference

7 January 2021

Chronic duloxetine treatment induces specific changes in the expression of BDNF transcripts and in the subcellular localization of the neurotrophin protein.

1 reference

7 January 2021

Norepinephrine induces BDNF and activates the PI-3K and MAPK cascades in embryonic hippocampal neurons

1 reference

7 January 2021

Neurotrophin and neuropeptide expression in mouse brain is regulated by knockout of the norepinephrine transporter

1 reference

7 January 2021

BDNF level in the rat prefrontal cortex increases following chronic but not acute treatment with duloxetine, a dual acting inhibitor of noradrenaline and serotonin re-uptake

1 reference

7 January 2021

Noradrenergic innervation of the dorsal medial prefrontal cortex modulates hypothalamo-pituitary-adrenal responses to acute emotional stress

1 reference

7 January 2021

Synergetic effects of quetiapine and venlafaxine in preventing the chronic restraint stress-induced decrease in cell proliferation and BDNF expression in rat hippocampus

1 reference

7 January 2021

Recovery of hippocampal cell proliferation and BDNF levels, both of which are reduced by repeated restraint stress, is accelerated by chronic venlafaxine

1 reference

7 January 2021

Revenge of the "sit": how lifestyle impacts neuronal and cognitive health through molecular systems that interface energy metabolism with neuronal plasticity

1 reference

7 January 2021

Neurotrophic factors and regulation of mood: role of exercise, diet and metabolism

1 reference

7 January 2021

Physical activity, exercise, depression and anxiety disorders

1 reference

7 January 2021

Physical activity dose-response effects on outcomes of depression and anxiety

1 reference

7 January 2021

Case history: the discovery of fluoxetine hydrochloride (Prozac)

1 reference

7 January 2021

Tryptophan-depletion challenge in depressed patients treated with desipramine or fluoxetine: implications for the role of serotonin in the mechanism of antidepressant action.

1 reference

7 January 2021

The serotonergic and noradrenergic systems of the hippocampus: their interactions and the effects of antidepressant treatments

1 reference

7 January 2021

Stress-induced plasticity of monoamine axons

1 reference

7 January 2021

Rate-independent inhibition by norepinephrine of 5-HT release from the somadendritic region of serotonergic neurons

1 reference

7 January 2021

Selective noradrenaline reuptake inhibition enhances serotonergic neuronal activity and transmitter release in the rat forebrain.

1 reference

7 January 2021

Treatment of posttraumatic stress disorder with venlafaxine extended release: a 6-month randomized controlled trial

1 reference

7 January 2021

Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents

1 reference

7 January 2021

Antagonism of the stress-induced increase in cortical norepinephrine output by the selective norepinephrine reuptake inhibitor reboxetine

1 reference

7 January 2021

Effects of reboxetine and sertraline treatments alone and in combination on the binding properties of cortical NMDA and beta1-adrenergic receptors in an animal model of depression

1 reference

7 January 2021

Noradrenaline in basic models of depression

1 reference

7 January 2021

Effects of reboxetine on Hamilton Depression Rating Scale factors from randomized, placebo-controlled trials in major depression

1 reference

7 January 2021

Effects of reboxetine on anxiety, agitation, and insomnia: results of a pooled evaluation of randomized clinical trials

1 reference

7 January 2021

Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor

1 reference

7 January 2021

Noradrenergic dysfunction and antidepressant treatment response

1 reference

7 January 2021

Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding

1 reference

7 January 2021

Amitriptyline: dual-action antidepressant?

1 reference

7 January 2021

Comorbid anxiety corresponds with neuropsychological dysfunction in unipolar depression.

1 reference

7 January 2021

A review on cognitive impairments in depressive and anxiety disorders with a focus on young adults

1 reference

7 January 2021

Adrenergic pharmacology and cognition: focus on the prefrontal cortex

1 reference

7 January 2021

Update on augmentation of antidepressant response in resistant depression

1 reference

7 January 2021

Anxiolytic property of estrogen related to the changes of the monoamine levels in various brain regions of ovariectomized rats.

1 reference

7 January 2021

Experience of the use of velaxin (venlafaxine) in anxious depression

1 reference

7 January 2021

Managing the patient with co-morbid depression and an anxiety disorder

1 reference

7 January 2021

Duloxetine in treatment of anxiety symptoms associated with depression

1 reference

7 January 2021

Strategies to enhance the therapeutic efficacy of antidepressants: targeting residual symptoms

1 reference

7 January 2021

Pharmacological approaches to the treatment of residual symptoms

1 reference

7 January 2021

Efficacy of continuation drug therapy of depression and anxiety: issues and methodologies

1 reference

7 January 2021

Identifiers

DOI

10.1002/DA.20642

1 reference

21 August 2017

1 reference